Key Points
- Beth Hecht sold 16,667 shares on Feb. 2 at an average price of $7.45 for about $124,169, leaving her with 1,243,174 shares (a 1.32% reduction in her position).
- The Feb. 2 sale continues a string of monthly disposals—16,667 shares each on Nov. 11, Dec. 1, Jan. 2 and Feb. 2—signaling consistent insider selling over recent months.
- Xeris trades near $7.36 with a market cap of roughly $1.22 billion, a negative P/E (-73.59), a 1‑year range of $3.44–$10.08, and an average analyst rating of "Moderate Buy" with a $10.08 price target.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $7.45, for a total transaction of $124,169.15. Following the transaction, the insider owned 1,243,174 shares of the company's stock, valued at $9,261,646.30. This represents a 1.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Beth Hecht also recently made the following trade(s):
- On Friday, January 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.43, for a total transaction of $123,835.81.
- On Monday, December 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.01, for a total transaction of $116,835.67.
- On Tuesday, November 11th, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.40, for a total transaction of $123,335.80.
Xeris Biopharma Price Performance
Shares of XERS stock opened at $7.36 on Tuesday. The company's fifty day simple moving average is $7.28 and its two-hundred day simple moving average is $7.49. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.44 and a 1 year high of $10.08. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -73.59 and a beta of 0.52.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million during the quarter, compared to analysts' expectations of $74.19 million. Equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.
Hedge Funds Weigh In On Xeris Biopharma
Large investors have recently added to or reduced their stakes in the business. AlphaQuest LLC bought a new position in shares of Xeris Biopharma during the third quarter valued at about $35,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company's stock valued at $63,000 after acquiring an additional 5,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company's stock valued at $63,000 after acquiring an additional 1,820 shares during the period. State of Alaska Department of Revenue bought a new position in Xeris Biopharma during the 3rd quarter worth approximately $68,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Xeris Biopharma in the 3rd quarter worth approximately $85,000. Hedge funds and other institutional investors own 42.75% of the company's stock.
Analyst Ratings Changes
XERS has been the topic of several analyst reports. Piper Sandler upped their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a "neutral" rating in a research report on Friday, November 7th. Wall Street Zen lowered shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a report on Saturday, November 8th. Zacks Research cut shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 30th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Xeris Biopharma in a research report on Friday, January 9th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $18.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $10.08.
Check Out Our Latest Analysis on Xeris Biopharma
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
